A Case of Interstitial Pneumonitis and Pancytopenia Following the Combination Therapy of Pegylated Interferon and Ribavirin |
Suh, Ji-Hyun
(Department of Internal Medicine, Dankook University College of Medicine)
Hahn, Sung-Hwahn (Department of Internal Medicine, Dankook University College of Medicine) Lee, Ji-Eun (Department of Internal Medicine, Dankook University College of Medicine) Han, Jin-Hyung (Department of Internal Medicine, Dankook University College of Medicine) Kim, Kyung-Mook (Department of Internal Medicine, Dankook University College of Medicine) Kim, Doh-Hyung (Department of Internal Medicine, Dankook University College of Medicine) Kim, Yon-Seop (Department of Internal Medicine, Dankook University College of Medicine) Park, Jae-Suk (Department of Internal Medicine, Dankook University College of Medicine) Jee, Young-Koo (Department of Internal Medicine, Dankook University College of Medicine) |
1 | NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19: 1-46. |
2 | Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. DOI ScienceOn |
3 | Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. DOI ScienceOn |
4 | Hwang SY, Lee HJ, Park KT, Kim KY, Lee SM, Park CW, et al. Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. Korean J Gastroenterol 2007;49:166-72. |
5 | Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994;105:939-41. DOI ScienceOn |
6 | Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003;124:406-10. DOI ScienceOn |
7 | Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91. DOI ScienceOn |
8 | Jeong HS, Oh JY, Jeon J, Seo MJ, Moon SH, Kim HS, et al. A case of interstitial pneumonitis after interferon therapy for chronic hepatitis C. Korean J Gastroenterol 1999;34:698-703. |
9 | Sohn BK, Sohn JH, Kim TY, Park YK, Jeon YC, Han DS. Pulmonary Toxicity by Pegylated Interferon -2a in a Patient with Chronic Hepatitis C. Korean J Hepatol 2007;13:103-7. |
10 | Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, et al. Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. Korean J Hepatol 2008;14:318-30. DOI ScienceOn |
11 | Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301-26. DOI ScienceOn |
12 | Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, et al. Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection. Korean J Hepatol 2010;16:38-48. DOI ScienceOn |
13 | Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-63. |
14 | Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994; 106:612-3. DOI ScienceOn |